Recurrent Melanoma Withdrawn Phase 2 Trials for Encorafenib (DB11718)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02263898Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 MutationsTreatment